Sonnenschein partner Randy Sabett will be the keynote speaker for the Drug Information Association event "Digital Signatures: Practical Strategies for Life Science Organizations."  Randy's speech will take place from 8:30-9 a.m. on May 13, 2008.

Standards-based electronic signatures (Digital Signatures) are essential to electronic submissions in compliance with FDA 21 CFR Part 11. However, for the biopharmaceutical industry, the benefits of digital signatures extend beyond compliance requirements to accelerated decision making, approval processes, cost reductions, and more efficient and paperless operations.  At the conclusion of this meeting, participants should be able to, explain the industry’s need to meet compliance requirements with electronic signatures; outline how digital signatures contribute to FDA initiatives for fully electronic transactions; and discuss the value of electronic signatures.